Clinical Trials Logo
  1. Home
  2. Peyronie's Disease
  3. NCT04786106

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's — iSCRIP  

Peyronie's Disease Clinical Trial

Official title:
Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial

Clinical Trial Summary

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

Clinical Trial Description

After eligible patients have been informed about the study protocol and risks and consent have been given, men will be randomly assigned into either the collagenase clostridium histolyticum + penile traction therapy (CCH + PTT) group or to the surgery + penile traction therapy (surgery + PTT) group. Those in the CCH + PTT group will receive the full 4 series of 8 Xiaflex injections with 1-3 days between each set of 2 injections and 6 weeks prior to the next series. Patients would then use the RestoreX traction device throughout the series to 3 months post-treatment. Those that were assigned the surgery + PTT treatment protocol would undergo surgery using either penile plication or incision and grafting, depending on the degree of curvature and erectile function. Traction using RestoreX will also be prescribed to these men 2-4 weeks post-operatively until 3 months post-treatment. Key clinical outcomes of both treatment protocols will be compared. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04786106
Study type Interventional
Source Charitable Union for the Research and Education of Peyronie's Disease
Contact
Status Active, not recruiting
Phase Phase 4
Start date December 30, 2020
Completion date February 15, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT01685437 - A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Phase 3
Completed NCT01430169 - Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Phase 2
Completed NCT01221597 - Study of AA4500 in the Treatment of Peyronie's Disease Phase 3
Recruiting NCT05108558 - Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders Phase 4
Recruiting NCT05147779 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Phase 1
Recruiting NCT03767452 - Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Phase 4
Completed NCT02267460 - An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Phase 3
Completed NCT01221623 - Study of AA4500 in the Treatment of Peyronie's Disease Phase 3
Completed NCT02298829 - Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Completed NCT01243411 - A Study of AA4500 in Men With Peyronie's Disease Phase 3
Completed NCT01578473 - Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Phase 1
Not yet recruiting NCT05855070 - Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease N/A
Completed NCT02072018 - Peyronie's Disease Treatment Protocol Phase 1
Terminated NCT05873595 - Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
Completed NCT00812838 - H-22411: BOTOX® for Peyronie's Disease Phase 2
Completed NCT02395029 - Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Phase 1
Completed NCT00755222 - The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Phase 2